NeoGenomics falls 13.7% after executive and board succession plan

What happened

NeoGenomics (NEO) fell 13.7% on October 6, 2026, after announcing an organized executive and board succession plan, according to Business Wire and Benzinga. The stock opened 4.5% above the previous close before reversing course, and the decline followed the succession announcement on Oct. 5–6, 2026. The drop stood out because the S&P 500 rose 0.6% on the day while the healthcare sector median fell 1.8%, making the move largely company-specific.

How big was the move

The stock fell 13.7% in a session that was 3.5 times a typical daily move for this stock, with trading volume at 2.3 times its 20-day average. Over the last five sessions the stock fell 11.9%, compared with the S&P 500 rising 1.9% in the same span. The session was 11.9 percentage points worse than the sector median. In the past five years the stock had 9 sessions with a decline of at least 13.7%; twenty trading days later the median result was a decline of 2.3%, and 4 of 9 were higher.

Taken together, the size and concentration of the move point to company-specific news as the likely driver: the shares moved far more than the market and its sector and the timing followed the succession announcement. The stock has a beta of 1.18, meaning it tends to move more than the market, which may magnify reactions to company developments.

The technical picture

The stock was 11.3% below its 20-day moving average and 5.0% below its 50-day moving average, while it remained 33.3% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 91 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) read 40, in a neutral range between 30 and 70.

NeoGenomics traded 18.1% below its 52-week high after the session. Over one month the stock fell 5.0%, over three months it rose 15.9%, and over one year it rose 81.4%. One year versus the S&P 500 the stock was 65.0 percentage points ahead. Volatility was 61% annualized over 60 days, a level lower than 55% of its own readings over five years. Those indicators show a stock that has enjoyed strong longer-term gains and momentum but that can still undergo sharp short-term reversals.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $766.3 million, which grew 11.2% from a year earlier and compared with growth of 10.9% one quarter earlier. Diluted earnings per share for that period were $-1.98. Gross margin was 42.9% (a year earlier: 43.9%), and operating margin was 8.6% (a year earlier: 16.7%). Free-cash-flow margin stood at 1.0% and return on invested capital read 5.0%.

The balance sheet showed net debt of 23.5 times EBITDA, and share count over one year increased by 2.3%. The market priced the stock at price to forward earnings of 90.4 times expected earnings and a free-cash-flow yield of 1.5%. Those valuation measures suggest the market is paying a steep premium for expected future earnings and cash generation despite relatively thin free-cash-flow margins and a high leverage metric on the balance sheet.

PromtFinance scores positioned the stock with Value 74 (Positive), Growth 62 (Neutral), Quality 24 (Very weak), Momentum 86 (Strong), Revisions 85 (Strong), and Stability 25 (Very weak). The profile highlights a mix of strong momentum and analyst revisions alongside weak quality and stability metrics, underscoring why investors may weigh near-term execution and capital structure risks against potential growth.

Earnings and analyst expectations

NeoGenomics last reported on July 28, 2026, with earnings per share of $0.05 against $0.03 expected, a result 49.0% above estimates. The company had beaten estimates in four consecutive quarters, with an average surprise over the last four reports of 55.5% above estimates. The typical two-day reaction after recent reports was that the stock fell 7.0%.

The next report was scheduled for October 27, 2026. Analyst coverage numbered 29, with 79% rating the stock Buy and a consensus rating of Buy. The consensus price target was $22.00, 33.3% above the closing price on October 6, 2026. That gap between the consensus target and the market price, alongside elevated forward multiples, may make upcoming guidance and the succession transition key near-term catalysts for the stock.

What to watch

• Oct. 27, 2026: next earnings report date
• The company disclosed the transition as an organized succession for its executive team and board of directors on Oct. 5–6, 2026
• Consensus price target $22.00, 33.3% above the closing price
• Net debt of 23.5 times EBITDA
• The stock had 91 consecutive trading days above the 200-day average